PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDostarlimab
Jemperli(dostarlimab)
Jemperli (dostarlimab) is an antibody pharmaceutical. Dostarlimab was first approved as Jemperli on 2021-04-21. It has been approved in Europe to treat endometrial neoplasms. It is known to target programmed cell death protein 1.
Download report
Favorite
FDA Novel Drug Approvals 2021
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Jemperli
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dostarlimab
Tradename
Proper name
Company
Number
Date
Products
Jemperlidostarlimab-gxlyGSKN-761174 RX2021-04-22
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
jemperliBiologic Licensing Application2025-09-02
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF07: Dostarlimab
HCPCS
Code
Description
J9272
Injection, dostarlimab-gxly, 10 mg
Clinical
Clinical Trials
96 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Endometrial neoplasmsD016889EFO_0004230—1511—8
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8010101——18
Ovarian neoplasmsD010051EFO_0003893C56231——6
Non-small-cell lung carcinomaD002289——142——6
Head and neck neoplasmsD006258——131——4
Neoplasm metastasisD009362EFO_0009708—111——3
Squamous cell carcinoma of head and neckD000077195——121——3
Colonic neoplasmsD003110—C18—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.026———6
Colorectal neoplasmsD015179——22———3
Lung neoplasmsD008175—C34.9022———3
Pancreatic neoplasmsD010190EFO_0003860C2512———3
Fallopian tube neoplasmsD005185——12———3
Rectal neoplasmsD012004——13———3
SarcomaD012509———2———2
Multiple myelomaD009101—C90.012———2
Plasma cell neoplasmsD054219——12———2
Breast neoplasmsD001943EFO_0003869C5011———2
Show 31 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C161————1
Gastrointestinal neoplasmsD005770—C26.91————1
Digestive system neoplasmsD004067——1————1
Neoplasms by siteD009371——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDostarlimab
INNdostarlimab
Description
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>7WSL:H|heavy chain EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH >7WSL:L|light chain DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQP EDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB7WSL
CAS-ID2022215-59-2
RxCUI—
ChEMBL IDCHEMBL4298124
ChEBI ID—
PubChem CID—
DrugBankDB15627
UNII IDP0GVQ9A4S5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,112 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,341 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use